Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Revance Therapeutics Inc RVNC

Healthcare
Revance Therapeutics, Inc. is a biotechnology company focused on developing and commercializing aesthetic and therapeutic offerings. The Company's portfolio includes DAXXIFY (DaxibotulinumtoxinA-lanm) for injection and the RHA Collection of dermal fillers in the United States. It has also partnered with Viatris to develop a biosimilar to onabotulinumtoxinA for injection and Fosun to... see more

Recent & Breaking News (NDAQ:RVNC)

RVNC EQUITY ALERT: ROSEN, LEADING INVESTOR COUNSEL, Encourages Revance Therapeutics, Inc. Investors with Losses to Inquire About Class Action Investigation - RVNC

PR Newswire October 18, 2021

Revance Therapeutics Investor Alert

Newsfile October 18, 2021

Ademi LLP Investigates Claims of Securities Fraud against Revance Therapeutics, Inc.

PR Newswire October 18, 2021

INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Revance Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

PR Newswire October 18, 2021

REVANCE THERAPEUTICS INVESTIGATION: Block & Leviton Is Investigating Revance Therapeutics, Inc. for Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm

Newsfile October 18, 2021

REVANCE ALERT: Bragar Eagel & Squire, P.C. is Investigating Revance Therapeutics, Inc. on Behalf of Revance Stockholders and Encourages Investors to Contact the Firm

Business Wire October 15, 2021

Revance Provides Regulatory Update on DaxibotulinumtoxinA for Injection for the Treatment of Moderate to Severe Glabellar (Frown) Lines

Business Wire October 15, 2021

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Revance Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

Business Wire October 15, 2021

RVNC BREAKING NEWS: ROSEN, A TOP RANKED LAW FIRM, Encourages Revance Therapeutics, Inc. Investors with Losses to Inquire About Class Action Investigation - RVNC

Business Wire October 14, 2021

HAGENS BERMAN, NATIONAL TRIAL ATTOREYS, Encourages Revance Therapeutics (RVNC) Investors with Significant Losses to Contact Firm's Attorneys Now, Firm Investigating Possible Securities Law Violations

PR Newswire October 14, 2021

EQUITY ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Revance Therapeutics, Inc.

Newsfile October 13, 2021

Revance Continues to Anticipate FDA Approval of DaxibotulinumtoxinA for Injection for the Treatment of Glabellar Lines in 2021

Business Wire October 12, 2021

REVANCE THERAPEUTICS INVESTIGATION: Block & Leviton Is Investigating Revance Therapeutics, Inc. For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm

Newsfile October 12, 2021

Revance Announces the Launch of OPUL(TM), the First-of-its-Kind Relational Commerce Platform for Aesthetic Practices

Business Wire October 11, 2021

Revance to Showcase Data from Phase 3 ASPEN-1 Clinical Trial Evaluating Efficacy, Duration of Effect and Safety of DaxibotulinumtoxinA for Injection for Cervical Dystonia at International Parkinson and Movement Disorder Society Virtual Congress 2021

Business Wire September 16, 2021

Revance Presents Data on the RHA® Collection of Dermal Fillers at the 2021 Virtual Skin of Color Update Meeting

Business Wire September 10, 2021

Revance to Participate in the Wells Fargo Securities Healthcare Conference

Business Wire September 2, 2021

Revance Announces Publication of Results on Static Glabellar Lines With Repeated Treatment of DaxibotulinumtoxinA for Injection From the SAKURA Clinical Program in Dermatologic Surgery

Business Wire September 1, 2021

Revance Reports Second Quarter 2021 Financial Results, Provides Corporate Update

Business Wire August 5, 2021

Revance to Release Second Quarter 2021 Financial Results on Thursday, August 5, 2021

Business Wire July 29, 2021